Emily Larrimer Savas

Emily Savas is an experienced litigator whose practice concentrates on pharmaceutical patent litigations and representation of generic drug manufacturers in Hatch-Waxman litigations. Emily is a registered patent agent and has experience negotiating sponsored research and clinical trial agreements.

Pharmaceutical Patent Litigation

Emily represents pharmaceutical clients through all stages of litigation arising under the Hatch-Waxman amendments to the Federal Food, Drug, and Cosmetic Act. Emily’s experience includes preparing Paragraph IV notice letters, invalidity and non-infringement contentions, all aspects of fact and expert discovery, claim construction proceedings, dispositive motion practice, preliminary injunction proceedings and trial.

Emily leads patent litigations concerning infringement and invalidity of patent claims directed to pharmaceutical formulations, crystalline forms of drug substances, x-ray powder diffraction peak patterns, pharmacokinetics and methods of treating a wide variety of diseases, including multiple sclerosis, depression, psoriasis, Parkinson’s disease, chronic obstructive pulmonary disease, overactive bladder, attention deficit disorder and narcolepsy.

Contract Negotiation

Emily returned to Locke Lord in 2013 after serving as Contracts Officer at University of California, San Diego, where she provided guidance to University researchers and business officers on medical industry contract terms and conditions and clinical trial agreements. She has experience negotiating contract terms regarding intellectual property ownership, material transfers, confidentiality and publication, export control regulations, dispute resolution and indemnification.

Patent and Trademark Prosecution

Emily is a registered patent agent with an advanced degree in molecular biology, and has extensive experience in both trademark prosecution and litigation. She has represented business owners in a variety of trademark prosecutions and disputes, including ownership and infringement.

Emily is currently pro bono counsel for a nonprofit organization promoting access to essential medicines and is responsible for its international trademark portfolio.

Her representative experience includes:

• Assist with defending a generic drug manufacturer in a Hatch-Waxman patent litigation involving three patents relating to esomeprazole magnesium trihydrate
• Assist with defending a generic drug manufacturer in a Hatch-Waxman patent litigation involving three patents relating to roflumilast
• Assist with defending a generic drug manufacturer in a Hatch-Waxman patent litigation involving mirabegron
• Assisted with defending a generic drug manufacturer in a Hatch-Waxman patent litigation involving 16 patents relating to sodium gamma-hydroxybutyrate and obtained settlement
• Represent a nonprofit organization in trademark prosecutions and general corporate matters
• Assisted with defending a generic drug manufacturer in a Hatch-Waxman patent litigation involving 18 patents relating to lisdexamphetamine
• Assisted with representation of light bulb manufacturer in declaratory judgment action involving a variety of electrical circuit and hardware patents
• Assisted with representation of a restaurant owner in a trademark litigation relating to trademark ownership
• Assisted with representation of a travel company in a trademark litigation relating to trademark infringement